DelveInsight’s “Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Social Anxiety Disorder, historical and forecasted epidemiology as well as the Social Anxiety Disorder market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Social Anxiety Disorder Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Social Anxiety Disorder Market Forecast. Click here to stay ahead in healthcare innovation @ Social Anxiety Disorder Market Size
Key Takeaways from the Social Anxiety Disorder Market Report
- April 2024:- VistaGen Therapeutics Inc.- US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-3).
- According to National Institute of Mental Health (NIMH), about 1 in 8 people (12.1%) experience socialAnxiety Disorder at some time in their life and in a given year. According to the U.S. National Institutes ofHealth (NIH), SAD is the third most common psychiatric condition after depression and substance abuse. Ofadults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment.
- As per Anxiety and Depression Association of America (ADAA) 2021, social anxiety disorder affects around15million adults, or 6.8% of US population. Many people frequently misdiagnosed as a result of the disease.thirty-six of people with social anxiety disorder experience symptoms for 10 years or more before seekingcare, according to a 2007 ADAA survey.
- According to Cambridge University (2020), epidemiologic surveys conducted across Europe indicated thatthe lifetime prevalence of Social anxiety disorder in general population is close to 7%.
- According to the analysis, females are more frequently diagnosed with SAD compared to males.
- The leading Social Anxiety Disorder Companies such as VistaGen Therapeutics Inc., EmpowerPharm Inc., and others.
- Promising Social Anxiety Disorder Therapies such as Fasedienol Nasal Spray, Cannabidiol oral solution, Sunflower Lecithin Oil in Capsule, and others.
Delve deep into the Social Anxiety Disorder Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Social Anxiety Disorder Market Forecast. Click here to shape the future @ Social Anxiety Disorder Epidemiology Insights
Social Anxiety Disorder Overview
Social Anxiety disorder (also called Social Phobia; SAD) is the most common mental health condition which causes extreme fear in social settings, and an intense, persistent fear of being watched and judged by others. People with social anxiety disorder have trouble talking to people, meeting new people, attend social gatherings and can also affect day-to-day activities. Social anxiety disorder can make a person fear from being judged or scrutinized by others. Patients may understand that their fears are irrational or unreasonable, but feel powerless to overcome them.
Social Anxiety Disorder Epidemiology Insights
- Total Prevalent Cases
- Severity specific cases
- Treated cases
- Social Anxiety Disorder Cases by age group
- Total Diagnosed Cases
Navigate the complexities of the Social Anxiety Disorder Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Social Anxiety Disorder Market Forecast. Click here to get more insights @ Social Anxiety Disorder Treatment Market
Social Anxiety Disorder Market Insights
GABAergics: Pregablin and gabapentin are GABAergic drugs proven beneficial for treating SAD. These agent havesimilar pharmacological profiles, working as calcium modulators to inhibit excitatory neurotransmitter release.Pregablin has a quicker onset of action that the FDA-approved antidepressants.
Social Anxiety Disorder Treatment Market Landscape
The Social Anxiety Disorder treatment includes psychological and pharmacological options. The psychological intervention termed cognitive-behavioral therapy (CBT) is used to help patients face barriers directly through exposure techniques, relaxation techniques, and training in social and conversational skills. It is always recommended that CBT should be always implemented ahead of pharmacologic therapy. Patients who manage their symptoms with psychological and pharmacologic treatment are more likely to achieve continued symptom-improvement benefits.
Unlock insights into the Social Anxiety Disorder Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Social Anxiety Disorder Market Forecast. Click here @ Social Anxiety Disorder Market Drivers and Barriers
Social Anxiety Disorder Market Dynamics
The Social Anxiety Disorder market dynamics is anticipated to change in the coming years owing to the improvement in the research and development undertaking. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with SAD.
Social Anxiety Disorder Drugs Uptake
- Vistagen Therapeutics is currently developing its lead product candidate PH94B nasal spray and is fundamentally different from all current drug treatments for SAD. PH94B binds to nasal chemosensory receptors which activates neural circuits that leads to rapid suppression of fear and anxiety. The drug is currently being studied in three Phase III (NCT05030350; NCT05011396; NCT04754802) clinical studies for the treatment of acute social anxiety disorder. The FDA has granted Fast-track designation for development of PH94B as a potential fast-acting acute treatment of SAD.
- BNC210 is a selective NAM of the α7 receptor being developed for the acute treatment of Social Anxiety Disorder. BNC 210 is Bionomics proprietary molecule in development for the treatment of SAD, posttraumatic stress disorder (PTSD) and anxiety disorders. It has a novel mechanism of action and extensive clinical and non-clinical studies have shown several properties which may be useful to treat SAD. Bionomics expects to initiate Phase II study for BNC 210 for acute treatment of SAD by 2021 and anticipating topline results by the end of 2022
Social Anxiety Disorder Market Drivers
- Less competitive scenarios
- Fast-acting innovative emerging therapies
- Increasing awareness and Prevalence
Social Anxiety Disorder Market Barriers
- Lack of robust pipeline
- Barriers to treatment
- Psychological and financial burden
Scope of the Social Anxiety Disorder Market Report
- Coverage- 7MM
- Social Anxiety Disorder Companies- VistaGen Therapeutics Inc., EmpowerPharm Inc., and others.
- Social Anxiety Disorder Therapies- Fasedienol Nasal Spray, Cannabidiol oral solution, Sunflower Lecithin Oil in Capsule, and others.
- Social Anxiety Disorder Market Dynamics: Social Anxiety Disorder Market drivers and Social Anxiety Disorder Market Barriers
- Social Anxiety Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Social Anxiety Disorder Unmet Needs, KOL’s views, Analyst’s views, Social Anxiety Disorder Market Access and Reimbursement
Gain a strategic edge in the Social Anxiety Disorder Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Social Anxiety Disorder Market Forecast. Click here to lead in advancements @ Social Anxiety Disorder Clinical Trials Assessment
Table of Content
1. Key Insights
2. Executive Summary of Social Anxiety Disorder (SAD)
3. Competitive Intelligence Analysis for Social Anxiety Disorder (SAD)
4. Social Anxiety Disorder (SAD): Market Overview at a Glance
5. Social Anxiety Disorder (SAD): Disease Background and Overview
6. Patient Journey
7. Social Anxiety Disorder (SAD) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Social Anxiety Disorder (SAD) Unmet Needs
10. Key Endpoints of Social Anxiety Disorder (SAD) Treatment
11. Social Anxiety Disorder (SAD) Marketed Products
12. Social Anxiety Disorder (SAD) Emerging Therapies
13. Social Anxiety Disorder (SAD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Social Anxiety Disorder (SAD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/